Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Investing Activities (2016 - 2025)

Cumberland Pharmaceuticals' Cash from Investing Activities history spans 16 years, with the latest figure at -$3.1 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 11363.83% year-over-year to -$3.1 million; the TTM value through Dec 2025 reached -$4.7 million, down 8236.82%, while the annual FY2025 figure was -$4.7 million, 8236.82% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$3.1 million at Cumberland Pharmaceuticals, down from -$690837.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $680805.0 in Q3 2022 and bottomed at -$13.5 million in Q1 2022.
  • The 5-year median for Cash from Investing Activities is -$108244.0 (2021), against an average of -$1.1 million.
  • The largest annual shift saw Cash from Investing Activities surged 728.95% in 2022 before it crashed 11363.83% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$26795.0 in 2021, then plummeted by 2291.39% to -$640772.0 in 2022, then soared by 72.77% to -$174453.0 in 2023, then soared by 84.63% to -$26809.0 in 2024, then plummeted by 11363.83% to -$3.1 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Cash from Investing Activities are -$3.1 million (Q4 2025), -$690837.0 (Q3 2025), and $285864.0 (Q2 2025).